[21]showing that a combination of low-dose MK886, ciglitazone (PPARγ ligand), andretinoic X receptor (RXRα; transcriptional partner of PPARγ),interacting in a superadditive manner, causes an inhibition of cell growth inlung cancer cell lines A549 and H1299. Here, PPARG is linked to cancer.